COO of Oculus Innovative Sciences Inc. (OCLS, Financial) James J Schutz buys 20,000 shares of OCLS on 12/09/2009 at an average price of $1.79 a share.
OCULUS INNOVATIVE SCIENCES, INC. is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized outside the United States (Europe, India and Mexico) for the treatment of infected wounds. The solutions derived from the Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. A recently completed U.S. Phase II clinical trial of Microcyn Technology met the primary endpoints of safety and efficacy for the treatment of mildly infected diabetic foot ulcers. Oculus Innovative Sciences Inc. has a market cap of $42 million; its shares were traded at around $1.71 with and P/S ratio of 7.8.
OCLS is in the portfolios of Chuck Royce of ROYCE & ASSOCIATES.
OCULUS INNOVATIVE SCIENCES, INC. is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized outside the United States (Europe, India and Mexico) for the treatment of infected wounds. The solutions derived from the Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. A recently completed U.S. Phase II clinical trial of Microcyn Technology met the primary endpoints of safety and efficacy for the treatment of mildly infected diabetic foot ulcers. Oculus Innovative Sciences Inc. has a market cap of $42 million; its shares were traded at around $1.71 with and P/S ratio of 7.8.
OCLS is in the portfolios of Chuck Royce of ROYCE & ASSOCIATES.
Insiders' Positions with OCLS
- Sell:: CEO Hojabr Alimi sold 315,000 shares of OCLS stock on 08/10/2009 at the average price of 2.09, the price of the stock has decreased by 18.18% since
Insiders' Positions with OCLS
- Buy:: CFO Robert E Miller bought 13,000 shares of OCLS stock on 11/11/2009 at the average price of 1.68, the price of the stock has increased by 1.79% since
Insiders' Positions with OCLS
- Buy:: Vice President James J Schutz bought 5,000 shares of OCLS stock on 08/12/2009 at the average price of 2.04, the price of the stock has decreased by 16.18% since
- Sell:: Director Richard K Conley sold 25,000 shares of OCLS stock on 09/10/2009 at the average price of 2.77, the price of the stock has decreased by 38.27% since
